Wall Street brokerages expect Proteostasis Therapeutics Inc (NASDAQ:PTI) to announce ($0.37) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Proteostasis Therapeutics’ earnings. The lowest EPS estimate is ($0.42) and the highest is ($0.31). Proteostasis Therapeutics posted earnings of ($0.36) per share during the same quarter last year, which indicates a negative year over year growth rate of 2.8%. The business is scheduled to announce its next quarterly earnings results on Friday, March 13th.
On average, analysts expect that Proteostasis Therapeutics will report full-year earnings of ($1.41) per share for the current fiscal year, with EPS estimates ranging from ($1.50) to ($1.23). For the next year, analysts anticipate that the firm will post earnings of ($1.50) per share, with EPS estimates ranging from ($1.61) to ($1.43). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Proteostasis Therapeutics.
Proteostasis Therapeutics (NASDAQ:PTI) last released its earnings results on Thursday, November 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.15.
Several equities analysts recently issued reports on PTI shares. HC Wainwright restated a “buy” rating on shares of Proteostasis Therapeutics in a report on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Proteostasis Therapeutics in a report on Friday, October 18th. Finally, Zacks Investment Research raised Proteostasis Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective on the stock in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $6.67.
In related news, major shareholder Enterprise Associates 12 New sold 117,164 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $2.45, for a total transaction of $287,051.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 19.80% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC raised its stake in shares of Proteostasis Therapeutics by 61.7% in the second quarter. Acadian Asset Management LLC now owns 373,324 shares of the company’s stock worth $365,000 after buying an additional 142,446 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Proteostasis Therapeutics during the 2nd quarter worth about $178,000. Paloma Partners Management Co acquired a new position in shares of Proteostasis Therapeutics during the 2nd quarter worth about $150,000. Jane Street Group LLC raised its holdings in shares of Proteostasis Therapeutics by 445.5% in the 2nd quarter. Jane Street Group LLC now owns 175,050 shares of the company’s stock valued at $171,000 after purchasing an additional 142,958 shares during the period. Finally, Squarepoint Ops LLC raised its holdings in shares of Proteostasis Therapeutics by 62.4% in the 3rd quarter. Squarepoint Ops LLC now owns 44,569 shares of the company’s stock valued at $38,000 after purchasing an additional 17,120 shares during the period. 41.60% of the stock is owned by institutional investors.
Shares of NASDAQ:PTI traded up $0.06 during trading on Thursday, reaching $2.46. The stock had a trading volume of 73,656 shares, compared to its average volume of 3,204,365. Proteostasis Therapeutics has a 52 week low of $0.61 and a 52 week high of $5.80. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.89 and a current ratio of 6.89. The firm’s fifty day moving average is $1.18 and its 200 day moving average is $0.97. The stock has a market cap of $124.75 million, a price-to-earnings ratio of -1.50 and a beta of 0.25.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study.
Read More: What are the benefits of a balanced fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.